NASDAQ$ACHC

Acadia Healthcare Company Inc. · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Acadia Healthcare reported solid revenue growth in Q4 2024, though earnings declined due to higher expenses.

Acadia Healthcare's Q4 2024 revenue increased by 4.2% year-over-year to $774.2 million, driven by higher patient volumes and growth in same-facility revenue. However, net income declined to $32.6 million, impacted by increased operating expenses and facility-related costs. Adjusted EPS came in at $0.64, while adjusted EBITDA totaled $153.1 million, reflecting a $14.3 million professional liability reserve adjustment and a $5.0 million impact from facility closures.

  • Total revenue increased by 4.2% year-over-year to $774.2 million.
  • Same-facility revenue grew by 4.7%, driven by a 3.2% increase in patient days.
  • Net income declined to $32.6 million, impacted by higher costs and facility closures.
  • Adjusted EPS improved to $0.64, while adjusted EBITDA reached $153.1 million.

Headline financials

Total Revenue

$774M

Previous: $743M+4.2%
EPS (adj)

$0.64

Previous: $0.87-26.4%
US Same-Facility Rev. Growth

4.7%

Previous: 10.3%-54.4%
US Same-Facility Patient Days Growth

3.2%

Previous: 2.9%+10.3%
US Same-Facility Admissions Growth

4.2%

No prior period
US Same-Facility Rev/Day Growth

1.4%

Previous: 7.1%-80.3%
Net Income

$32.6M

Previous: $57.7M-43.5%
Operating Income

$38M

Previous: $125M-69.6%

Revenue & EPS history

Acadia Healthcare · Revenue · Quarterly

$774M

Q4 2024+4.2%vs Q4 2023
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Forward guidance

Acadia Healthcare expects continued revenue growth in 2025, with stable margins and expansion in patient capacity.

Tailwinds

  • Full-year 2025 revenue projected between $3.3 billion and $3.4 billion.
  • Adjusted EBITDA expected to be in the range of $675 million to $725 million.
  • Adjusted EPS guidance set at $2.50 to $2.80.
  • Expansion plans include adding 800 to 1,000 new beds.
  • Continued investments in joint ventures and technology to drive growth.

Headwinds

  • Interest expense expected to increase to $130 million to $140 million.
  • Depreciation and amortization expenses projected at $175 million to $185 million.
  • Startup losses for newly opened facilities expected to rise to $50 million to $55 million.
  • Potential net decrease in Medicaid supplemental payments of up to $15 million.
  • Expansion capital expenditures projected to be between $525 million and $575 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+1.5%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+2.5%

Avg return

30 days after

60%

38 / 63 earnings

Positive

+23.1%

Q3 2020

Best reaction

-26.9%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.5%+0.3%-16.0%
Q4 2025+21.4%+36.5%+33.4%
Q3 2025-5.5%-10.2%-25.2%
Q1 2025+4.2%+1.2%-14.4%
Q4 2024-25.5%-26.3%-25.2%
Q3 2024-17.3%-18.0%-21.3%
Q2 2024+10.0%+5.4%+21.6%
Q1 2024-9.8%-8.3%-6.8%
Q4 2023-2.4%-1.8%-7.3%
Q3 2023-1.7%+1.1%+0.5%
Q2 2023+7.8%+6.5%+2.9%
Q1 2023-1.3%-4.4%-6.0%
Q4 2022-9.6%-7.3%-12.1%
Q3 2022-3.4%-5.5%+7.2%
Q2 2022+3.6%+3.9%+4.8%
Q1 2022+8.0%+5.4%+6.4%
Q4 2021+6.5%+9.3%+15.3%
Q3 2021+10.5%+11.8%+3.0%
Q2 2021+3.1%+1.3%+8.0%
Q1 2021-1.1%+1.1%+4.4%
Q4 2020+1.5%+2.5%+6.0%
Q3 2020+23.1%+28.7%+49.1%
Q2 2020+2.3%+2.7%-0.1%
Q1 2020+16.7%+18.2%+26.7%
Q4 2019-5.9%+6.0%+100.5%
Q3 2019-3.5%-2.0%+2.5%
Q2 2019-3.3%-12.0%-19.6%
Q1 2019+0.0%+3.2%+1.4%
Q4 2018+15.9%+11.7%+11.7%
Q3 2018-12.8%-5.0%-26.0%
Q2 2018-10.6%-7.4%-8.0%
Q1 2018+9.0%+11.7%+13.0%
Q4 2017+8.5%+6.8%+8.4%
Q3 2017-26.9%-25.6%-30.7%
Q2 2017+7.6%+5.7%-7.5%
Q1 2017-3.1%+0.0%-2.4%
Q4 2016+5.4%+4.9%-1.7%
Q3 2016+3.1%+3.8%+5.9%
Q2 2016-1.3%-0.8%-4.8%
Q1 2016-0.8%
Q4 2015+5.7%
Q3 2015+9.4%
Q2 2015+3.4%
Q1 2015-2.9%
Q4 2014-0.4%
Q3 2014+11.2%
Q2 2014-2.1%
Q1 2014+0.4%
Q4 2013-2.8%
Q3 2013+9.0%
Q2 2013+8.2%
Q1 2013+2.9%
Q4 2009+2.3%
Q4 2012+0.1%
Q3 2012+2.3%
Q2 2012+7.5%
Q2 2011+4.4%
Q1 2012+6.5%
Q1 2011-1.0%
Q4 2011+3.3%
Q4 2010+0.1%
Q3 2011+0.1%
Q3 2010+0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro